论文部分内容阅读
目的:探讨血清1,25-二羟维生素D3和总免疫球蛋白E(Ig E)在喘息患儿体内的含量变化,以及孟鲁司特对两种物质的干预作用。方法:选取我院收治的60例6个月~3岁的喘息患儿,分为非干预组和孟鲁司特干预组各30例,同时选取同年龄段的健康体检儿童30例作为对照组。采用放射免疫法测定血清1,25-二羟维生素D3,酶联免疫法测定血清总Ig E水平,观察三组儿童血清1,25-二羟维生素D3和Ig E的差异,以及喘息患儿治疗前后两种物质的变化,并比较非干预组和孟鲁司特干预组的临床疗效。结果:喘息患儿血清1,25-二羟维生素D3明显低于健康儿童(P<0.05),血清总Ig E水平明显高于健康儿童(P<0.05),孟鲁司特干预组临床疗效优于非干预组(P<0.01),孟鲁司特可以降低喘息患儿血清总Ig E水平(t=22.496,P<0.01)。结论:1,25-二羟维生素D3和血清总Ig E均参与喘息患儿的免疫调节机制,孟鲁司特是治疗喘息患儿一种安全有效的药物,并且通过降低血清总Ig E减轻过敏性喘息。
Objective: To investigate the changes of serum 1,25 - dihydroxyvitamin D3 and total immunoglobulin E (Ig E) in asthmatic children and the intervention of montelukast on the two substances. Methods: Sixty children aged 6 months to 3 years old who were admitted to our hospital were randomly divided into non-intervention group and montelukast intervention group of 30 cases. 30 healthy children of the same age were selected as the control group . The serum 1,25-dihydroxyvitamin D3 was determined by radioimmunoassay and the serum total IgE was measured by enzyme-linked immunosorbent assay. The differences of serum 1,25-dihydroxyvitamin D3 and IgE in the three groups were observed, and the treatment of asthmatic children Before and after the changes of two substances, and non-intervention group and montelukast intervention group clinical efficacy. Results: Serum 1,25-dihydroxyvitamin D3 was significantly lower in asthmatic children than in healthy children (P <0.05), and serum IgE levels were significantly higher than those in healthy children (P <0.05). The clinical efficacy of montelukast intervention group In the non-intervention group (P <0.01), montelukast could reduce the serum total IgE level in asthmatic children (t = 22.496, P <0.01). Conclusion: Both 1,25-dihydroxyvitamin D3 and total serum IgE are involved in the immunoregulatory mechanism of asthmatic children. Montelukast is a safe and effective drug for the treatment of asthmatic children and alleviates the allergy by reducing the total serum IgE Sexual breathing.